Nutshell Therapeutics (Shanghai) received FDA IND clearance for NTS-231, a covalent allosteric molecular glue degrader of NRF2 designed to induce KEAP1-dependent NRF2 degradation. The company said the molecule was identified using its AI-driven Allostar platform, which screens for covalent allosteric binders. The IND authorization moves NTS-231 into U.S. clinical planning and reinforces ongoing pharmaceutical interest in NRF2-pathway modulation, a target space linked to oxidative stress and inflammatory signaling. For investors, IND clearance typically reduces near-term regulatory risk and accelerates trial initiation preparations.